RADNET INC

RDNTNASDAQ

🏆 #935 by market capEarnings Nov 11US Equity

$76.34▼ $0.93 (−1.22%)

Live

1h—

24h▼ 1.2%

7d▲ 13.7%

14d▲ 20.4%

30d▲ 20.7%

1y▲ 20.1%

🏦Market Cap

$6.00B

Small Cap

📈Revenue Growth (YoY)

+14.7%

Healthy

📊Gross Margin

24.1%

Moderate

💵FCF Margin

5.1%

Moderate

⚖️P/S Ratio

2.8x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $75.89 – $77.08
52-Week Range: $50.82 – $85.84
Volume: $3.36B
Avg Volume: $4.44B
Shares Outstanding: 78.6M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $2.04B
Last Q Revenue: $623M
P/E Ratio: —
P/S Ratio: 2.8x
EPS (TTM): $-0.18
Dividend Yield: —

Why Investors Own RDNT

✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2.04B▲ +22.1% YoY

Gross Margin (TTM)

34.2%▲ +3.2% YoY

Operating Income (TTM)

$581M▲ +22.1% YoY

Free Cash Flow (TTM)

$155M▲ +22.1% YoY

About RADNET INC

RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.

🦦